Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Arbutus Biopharma (ABUS) just unveiled an announcement.
At Arbutus Biopharma Corporation’s 2024 Annual General and Special Meeting, shareholders backed significant changes to its 2016 Omnibus Share and Incentive Plan, notably a substantial increase in the number of shares allocated for issuance and incentive stock options. Additionally, they elected director nominees, endorsed executive compensation, and confirmed Ernst & Young LLP as the independent auditor for the upcoming fiscal year, highlighting a strong alignment between the company’s management and its shareholders’ interests.
Learn more about ABUS stock on TipRanks’ Stock Analysis page.
Trending Articles:
- “More Hopeful than Real”: Is a Bidding War Brewing for Warner Bros. Discovery Stock (NASDAQ:WBD)?
- “Didn’t Develop the Way Automakers Thought.” Ford Notches Up, Reconsidering the EV Market
- “Our Focus is Increasingly…on Inference”: Intel Stock (NASDAQ:INTC) Jumps With Crescent Island Testing Next Year